Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.
R. F. Marschke
Research Funding - Cylene
M. J. Borad
Research Funding - Cylene
R. W. McFarland
Research Funding - Cylene
R. H. Alvarez
Research Funding - Cylene
J. K. Lim
Employment or Leadership Position - Cylene
C. S. Padgett
Employment or Leadership Position - Cylene
D. D. Von Hoff
Employment or Leadership Position - Cylene
Consultant or Advisory Role - Cylene
Stock Ownership - Cylene
S. E. O'Brien
Employment or Leadership Position - Cylene
D. W. Northfelt
Research Funding - Cylene